Johnson & Johnson (JNJ) Assets (2009 - 2026)
Johnson & Johnson (JNJ) posted Assets of $201.1 billion for Q2 2026, little changed sequentially from $200.9 billion in Q1 2026, and up 3.97% YoY from $193.4 billion in Q2 2025.
Johnson & Johnson (JNJ) Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Assets for 18 years, with the latest figure at $201.1 billion in Q2 2026.
- Quarterly Assets rose 3.97% year-over-year to $201.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $201.1 billion (up 3.97% YoY) and the FY2025 annual result came in at $199.2 billion, up 10.61% from the prior year.
- Assets was little changed at $201.1 billion in Q2 2026 per JNJ's latest filing, from $200.9 billion in the prior quarter.
- Over five years, Assets peaked at $201.1 billion in Q2 2026 and troughed at $166.1 billion in Q4 2023.
- A 5-year average of $185.0 billion and a median of $182.0 billion in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets slipped 12.25% in 2024, then climbed 12.62% in 2025.
- Over 5 years, Assets stood at $175.1 billion in 2022, then slipped by 4.32% to $167.6 billion in 2023, then climbed by 7.49% to $180.1 billion in 2024, then climbed by 10.61% to $199.2 billion in 2025, then gained by 0.93% to $201.1 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $201.1 billion, $200.9 billion, and $199.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 201.06 Bn |
| Mar 29, 2026 | 200.89 Bn |
| Dec 28, 2025 | 199.21 Bn |
| Sep 28, 2025 | 192.82 Bn |
| Jun 29, 2025 | 193.39 Bn |
| Mar 30, 2025 | 193.67 Bn |
| Dec 29, 2024 | 180.10 Bn |
| Sep 29, 2024 | 178.29 Bn |
| Jun 30, 2024 | 181.09 Bn |
| Mar 31, 2024 | 171.97 Bn |
| Dec 31, 2023 | 167.56 Bn |
| Oct 1, 2023 | 166.06 Bn |
| Jul 2, 2023 | 191.69 Bn |
| Apr 2, 2023 | 195.97 Bn |
| Jan 1, 2023 | 187.38 Bn |
| Oct 2, 2022 | 175.12 Bn |
| Jul 3, 2022 | 177.72 Bn |
| Apr 3, 2022 | 178.36 Bn |
| Jan 2, 2022 | 182.02 Bn |
| Oct 3, 2021 | 179.23 Bn |